AG˹ٷ

STOCK TITAN

[FWP] Morgan Stanley Free Writing Prospectus

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
FWP
Rhea-AI Filing Summary

Agilysys, Inc. (AGYS) has filed a Form 144 indicating a forthcoming sale of 258 common shares, valued at approximately $29,253.59, through Fidelity Brokerage Services on 07 July 2025. The shares represent less than 0.001% of the 28,017,312 shares outstanding. The seller acquired the stock one day earlier (06 June 2025) via restricted-stock vesting as compensation. The same individual, identified as Chris Robertson, sold 500 shares for $55,632.75 on 12 June 2025. No additional financial metrics, earnings data, or strategic disclosures accompany the notice. The filing fulfils SEC Rule 144 requirements and signals a routine, small-scale insider liquidity event rather than a material corporate development.

Agilysys, Inc. (AGYS) ha depositato un Modulo 144 indicando una prossima vendita di 258 azioni ordinarie, valutate approssimativamente 29.253,59 $, tramite Fidelity Brokerage Services il 07 luglio 2025. Le azioni rappresentano meno dello 0,001% delle 28.017.312 azioni in circolazione. Il venditore ha acquisito le azioni un giorno prima (06 giugno 2025) tramite vesting di azioni vincolate come compenso. La stessa persona, identificata come Chris Robertson, ha venduto 500 azioni per 55.632,75 $ il 12 giugno 2025. Nessun dato finanziario aggiuntivo, risultati economici o comunicazioni strategiche accompagnano l'avviso. Il deposito soddisfa i requisiti della Regola 144 della SEC e rappresenta un evento di liquidità interno di piccola entità e di routine, piuttosto che uno sviluppo aziendale rilevante.

Agilysys, Inc. (AGYS) ha presentado un Formulario 144 indicando una próxima venta de 258 acciones comunes, valoradas aproximadamente en 29,253.59 $, a través de Fidelity Brokerage Services el 07 de julio de 2025. Las acciones representan menos del 0.001% de las 28,017,312 acciones en circulación. El vendedor adquirió las acciones un día antes (06 de junio de 2025) mediante vesting de acciones restringidas como compensación. La misma persona, identificada como Chris Robertson, vendió 500 acciones por 55,632.75 $ el 12 de junio de 2025. No se acompañan datos financieros adicionales, resultados o revelaciones estratégicas. La presentación cumple con los requisitos de la Regla 144 de la SEC y señala un evento rutinario de liquidez interna de pequeña escala, en lugar de un desarrollo corporativo significativo.

Agilysys, Inc. (AGYS)� 2025� 7� 7� Fidelity Brokerage Services� 통해 � 29,253.59달러 상당� 258� 보통� 매각 예정임을 알리� Form 144� 제출했습니다. 해당 주식은 전체 발행 주식 28,017,312주의 0.001% 미만� 해당합니�. 매도자는 보상으로� 제한 주식 베스�� 통해 2025� 6� 6� 하루 전에 주식� 취득했습니다. 동일 인물� Chris Robertson은 2025� 6� 12� 500�55,632.75달러� 매도했습니다. 추가 재무 지�, 수익 데이� 또는 전략� 공시� 없습니다. � 제출은 SEC 규칙 144 요건� 충족하며, 중대� 기업 발전보다� 일상적이� 소규� 내부� 유동� 이벤트임� 나타냅니�.

Agilysys, Inc. (AGYS) a déposé un Formulaire 144 indiquant une prochaine vente de 258 actions ordinaires, d'une valeur d'environ 29 253,59 $, via Fidelity Brokerage Services le 07 juillet 2025. Ces actions représentent moins de 0,001 % des 28 017 312 actions en circulation. Le vendeur a acquis les actions un jour plus tôt (06 juin 2025) par le biais d'un vesting d'actions restreintes en guise de rémunération. La même personne, identifiée comme Chris Robertson, a vendu 500 actions pour 55 632,75 $ le 12 juin 2025. Aucune donnée financière supplémentaire, résultat ou divulgation stratégique n'accompagne cet avis. Le dépôt satisfait aux exigences de la règle 144 de la SEC et signale un événement de liquidité interne de petite envergure et de routine plutôt qu'un développement majeur de l'entreprise.

Agilysys, Inc. (AGYS) hat eine Formular 144 eingereicht, die einen bevorstehenden Verkauf von 258 Stammaktien im Wert von etwa 29.253,59 $ über Fidelity Brokerage Services am 07. Juli 2025 anzeigt. Die Aktien repräsentieren weniger als 0,001 % der 28.017.312 ausstehenden Aktien. Der Verkäufer erwarb die Aktien einen Tag zuvor (06. Juni 2025) durch Restricted-Stock-Vesting als Vergütung. Dieselbe Person, identifiziert als Chris Robertson, verkaufte am 12. Juni 2025 500 Aktien ü 55.632,75 $. Es werden keine weiteren finanziellen Kennzahlen, Gewinnangaben oder strategischen Offenlegungen mit der Mitteilung bereitgestellt. Die Einreichung erfüllt die Anforderungen der SEC-Regel 144 und signalisiert ein routinemäßiges, kleines Insider-Liquiditätsereignis und keine wesentliche unternehmerische Entwicklung.

Positive
  • None.
Negative
  • None.

Insights

TL;DR � Routine insider sale; immaterial to AGYS valuation.

The proposed sale equals roughly 0.0009% of shares outstanding and follows a recent 500-share sale by the same insider. Dollar value is negligible versus AGYS’s daily trading volume, implying no valuation impact. Such filings are common after restricted-stock vesting and do not, by themselves, imply negative sentiment. I view the disclosure as neutral for investors.

TL;DR � Compliance with Rule 144; no governance red flags.

The insider affirms no undisclosed adverse information, and the sale is properly scheduled via a broker. Absence of a 10b5-1 plan date suggests discretionary timing, yet the minimal size and prompt disclosure mitigate governance concern. From a stewardship perspective, the event is non-impactful.

Agilysys, Inc. (AGYS) ha depositato un Modulo 144 indicando una prossima vendita di 258 azioni ordinarie, valutate approssimativamente 29.253,59 $, tramite Fidelity Brokerage Services il 07 luglio 2025. Le azioni rappresentano meno dello 0,001% delle 28.017.312 azioni in circolazione. Il venditore ha acquisito le azioni un giorno prima (06 giugno 2025) tramite vesting di azioni vincolate come compenso. La stessa persona, identificata come Chris Robertson, ha venduto 500 azioni per 55.632,75 $ il 12 giugno 2025. Nessun dato finanziario aggiuntivo, risultati economici o comunicazioni strategiche accompagnano l'avviso. Il deposito soddisfa i requisiti della Regola 144 della SEC e rappresenta un evento di liquidità interno di piccola entità e di routine, piuttosto che uno sviluppo aziendale rilevante.

Agilysys, Inc. (AGYS) ha presentado un Formulario 144 indicando una próxima venta de 258 acciones comunes, valoradas aproximadamente en 29,253.59 $, a través de Fidelity Brokerage Services el 07 de julio de 2025. Las acciones representan menos del 0.001% de las 28,017,312 acciones en circulación. El vendedor adquirió las acciones un día antes (06 de junio de 2025) mediante vesting de acciones restringidas como compensación. La misma persona, identificada como Chris Robertson, vendió 500 acciones por 55,632.75 $ el 12 de junio de 2025. No se acompañan datos financieros adicionales, resultados o revelaciones estratégicas. La presentación cumple con los requisitos de la Regla 144 de la SEC y señala un evento rutinario de liquidez interna de pequeña escala, en lugar de un desarrollo corporativo significativo.

Agilysys, Inc. (AGYS)� 2025� 7� 7� Fidelity Brokerage Services� 통해 � 29,253.59달러 상당� 258� 보통� 매각 예정임을 알리� Form 144� 제출했습니다. 해당 주식은 전체 발행 주식 28,017,312주의 0.001% 미만� 해당합니�. 매도자는 보상으로� 제한 주식 베스�� 통해 2025� 6� 6� 하루 전에 주식� 취득했습니다. 동일 인물� Chris Robertson은 2025� 6� 12� 500�55,632.75달러� 매도했습니다. 추가 재무 지�, 수익 데이� 또는 전략� 공시� 없습니다. � 제출은 SEC 규칙 144 요건� 충족하며, 중대� 기업 발전보다� 일상적이� 소규� 내부� 유동� 이벤트임� 나타냅니�.

Agilysys, Inc. (AGYS) a déposé un Formulaire 144 indiquant une prochaine vente de 258 actions ordinaires, d'une valeur d'environ 29 253,59 $, via Fidelity Brokerage Services le 07 juillet 2025. Ces actions représentent moins de 0,001 % des 28 017 312 actions en circulation. Le vendeur a acquis les actions un jour plus tôt (06 juin 2025) par le biais d'un vesting d'actions restreintes en guise de rémunération. La même personne, identifiée comme Chris Robertson, a vendu 500 actions pour 55 632,75 $ le 12 juin 2025. Aucune donnée financière supplémentaire, résultat ou divulgation stratégique n'accompagne cet avis. Le dépôt satisfait aux exigences de la règle 144 de la SEC et signale un événement de liquidité interne de petite envergure et de routine plutôt qu'un développement majeur de l'entreprise.

Agilysys, Inc. (AGYS) hat eine Formular 144 eingereicht, die einen bevorstehenden Verkauf von 258 Stammaktien im Wert von etwa 29.253,59 $ über Fidelity Brokerage Services am 07. Juli 2025 anzeigt. Die Aktien repräsentieren weniger als 0,001 % der 28.017.312 ausstehenden Aktien. Der Verkäufer erwarb die Aktien einen Tag zuvor (06. Juni 2025) durch Restricted-Stock-Vesting als Vergütung. Dieselbe Person, identifiziert als Chris Robertson, verkaufte am 12. Juni 2025 500 Aktien ü 55.632,75 $. Es werden keine weiteren finanziellen Kennzahlen, Gewinnangaben oder strategischen Offenlegungen mit der Mitteilung bereitgestellt. Die Einreichung erfüllt die Anforderungen der SEC-Regel 144 und signalisiert ein routinemäßiges, kleines Insider-Liquiditätsereignis und keine wesentliche unternehmerische Entwicklung.

Free Writing Prospectus to Preliminary Pricing Supplement No. 9,080

Registration Statement Nos. 333-275587; 333-275587-01

Dated July 1, 2025; Filed pursuant to Rule 433

Morgan Stanley

Worst-of INDU, NDX and RTY Callable Contingent Income Securities due August 3, 2028

This document provides a summary of the terms of the securities. Investors must carefully review the accompanying preliminary pricing supplement referenced below, product supplement, index supplement and prospectus, and the “Risk Considerations” on the following page, prior to making an investment decision.

Terms

Issuer:

Morgan Stanley Finance LLC

Guarantor:

Morgan Stanley

Underliers:

Dow Jones Industrial AverageSM (INDU), Nasdaq-100 Index® (NDX) and Russell 2000® Index (RTY)

Call feature:

Quarterly, based on the output of a risk neutral valuation model. See the accompanying preliminary pricing supplement.

Redemption dates:

Quarterly

Contingent coupon:

8.25% to 10.25% per annum

Coupon payment dates:

Quarterly

Coupon barrier level:

70% of the initial level for each underlier

Downside threshold level:

70% of the initial level for each underlier

Pricing date:

July 31, 2025

Final observation date:

July 31, 2028

Maturity date:

August 3, 2028

CUSIP:

61778NCB5

Estimated value:

$954.90 per security, or within $45.00 of that estimate

Preliminary pricing supplement:

https://www.sec.gov/Archives/edgar/data/895421/000183988225035963/ms9080_424b2-19653.htm

1All payments are subject to our credit risk

 

Hypothetical Payment at Maturity1

(if the securities have not been redeemed)

% Change in Closing Level of the Worst Performing Underlier

Payment at Maturity per Security (excluding any contingent coupon payable at maturity)

+100.00%

$1,000.00

+80.00%

$1,000.00

+60.00%

$1,000.00

+40.00%

$1,000.00

+20.00%

$1,000.00

0.00%

$1,000.00

-20.00%

$1,000.00

-30.00%

$1,000.00

-31.00%

$690.00

-40.00%

$600.00

-60.00%

$400.00

-80.00%

$200.00

-100.00%

$0.00

 


 

The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling toll-free 1-800-584-6837.

Underlier(s)

For more information about the underlier(s), including historical performance information, see the accompanying preliminary pricing supplement.

Risk Considerations

The risks set forth below are discussed in more detail in the “Risk Factors” section in the accompanying preliminary pricing supplement. Please review those risk factors carefully prior to making an investment decision.

Risks Relating to an Investment in the Securities

The securities do not guarantee the return of any principal.

The securities do not provide for the regular payment of interest.

Payment of the contingent coupon is based on the closing levels of the underliers on only the related observation date at the end of the related interest period.

Investors will not participate in any appreciation in the value of any underlier.

The securities are subject to early redemption risk.

The market price of the securities may be influenced by many unpredictable factors.

The securities are subject to our credit risk, and any actual or anticipated changes to our credit ratings or credit spreads may adversely affect the market value of the securities.

As a finance subsidiary, MSFL has no independent operations and will have no independent assets.

The rate we are willing to pay for securities of this type, maturity and issuance size is likely to be lower than the rate implied by our secondary market credit spreads and advantageous to us. Both the lower rate and the inclusion of costs associated with issuing, selling, structuring and hedging the securities in the original issue price reduce the economic terms of the securities, cause the estimated value of the securities to be less than the original issue price and will adversely affect secondary market prices.

The estimated value of the securities is determined by reference to our pricing and valuation models, which may differ from those of other dealers and is not a maximum or minimum secondary market price.

The securities will not be listed on any securities exchange and secondary trading may be limited.

As discussed in more detail in the accompanying product supplement, investing in the securities is not equivalent to investing in the underlier(s).

The U.S. federal income tax consequences of an investment in the securities are uncertain.

Risks Relating to the Underlier(s)

Because your return on the securities will depend upon the performance of the underlier(s), the securities are subject to the following risk(s), as discussed in more detail in the accompanying product supplement.

oYou are exposed to the price risk of each underlier.

oBecause the securities are linked to the performance of the worst performing underlier, you are exposed to a greater risk of not receiving a positive return on the securities and/or sustaining a significant loss on your investment than if the securities were linked to just one underlier.

oAdjustments to an underlying index could adversely affect the value of the securities.

The securities are subject to risks associated with small-capitalization companies.

Risks Relating to Conflicts of Interest

The calculation agent, which is a subsidiary of Morgan Stanley and an affiliate of MSFL, will make determinations with respect to the securities.

Hedging and trading activity by our affiliates could potentially adversely affect the value of the securities.

Tax Considerations

You should review carefully the discussion in the accompanying preliminary pricing supplement under the caption “Additional Information About the Securities–United States federal income tax considerations” concerning the U.S. federal income tax consequences of an investment in the securities, and you should consult your tax adviser.

 

FAQ

How many AGYS shares are being sold under this Form 144?

The filing covers 258 common shares of Agilysys, Inc.

What is the estimated market value of the AGYS shares to be sold?

The aggregate market value is $29,253.59 based on the filing.

Who is the insider selling AGYS shares?

The seller is Chris Robertson, as noted in the past-transactions section.

When will the AGYS share sale occur?

The approximate sale date disclosed is 07/01/2025.

How significant is this sale relative to total AGYS shares outstanding?

The 258 shares represent less than 0.001% of the 28,017,312 shares outstanding.

Did the insider recently sell additional AGYS shares?

Yes. 500 shares were sold on 06/12/2025 for $55,632.75.
Morgan Stanley

NYSE:MS

MS Rankings

MS Latest News

MS Latest SEC Filings

MS Stock Data

218.03B
1.22B
23.64%
62.12%
0.89%
Capital Markets
Security Brokers, Dealers & Flotation Companies
United States
NEW YORK